KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Amortizatization of Intangibles: 2019-2024

Historic Amortizatization of Intangibles for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $78.3 million.

  • AbCellera Biologics' Amortizatization of Intangibles fell 93.99% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year decrease of 78.58%. This contributed to the annual value of $78.3 million for FY2024, which is 572.96% up from last year.
  • As of FY2024, AbCellera Biologics' Amortizatization of Intangibles stood at $78.3 million, which was up 572.96% from $11.6 million recorded in FY2023.
  • AbCellera Biologics' 5-year Amortizatization of Intangibles high stood at $78.3 million for FY2024, and its period low was $2.5 million during FY2020.
  • For the 3-year period, AbCellera Biologics' Amortizatization of Intangibles averaged around $36.3 million, with its median value being $18.9 million (2022).
  • As far as peak fluctuations go, AbCellera Biologics' Amortizatization of Intangibles spiked by 936.63% in 2020, and later tumbled by 38.40% in 2023.
  • Yearly analysis of 5 years shows AbCellera Biologics' Amortizatization of Intangibles stood at $2.5 million in 2020, then skyrocketed by 299.44% to $10.1 million in 2021, then surged by 87.74% to $18.9 million in 2022, then tumbled by 38.40% to $11.6 million in 2023, then surged by 572.96% to $78.3 million in 2024.